MAA 868

Drug Profile

MAA 868

Alternative Names: MAA868

Latest Information Update: 16 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis Pharmaceuticals
  • Class Anticoagulants; Antithrombotics; Monoclonal antibodies
  • Mechanism of Action Factor IX inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Stroke

Most Recent Events

  • 31 Jan 2018 Novartis announces intention to submit an IND application for MAA 868 for Stroke prevention in atrial fibrillation in 2021 (Novartis Results, July 2017)
  • 12 Jan 2018 Novartis Pharmaceuticals plans a phase II trial for Atrial Fibrillation in March 2018 , (NCT03398434)
  • 11 Jan 2018 Phase-II clinical trials in Stroke (Prevention) in Switzerland (SC) (Novartis pipeline, January 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top